Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $28.00 to $38.00 in a report released on ...
Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...
While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.